China News Service, Beijing, June 17 (Reporter Zhang Su) "In this study, the combination therapy of sintilimab and bevacizumab provided the world's largest hepatitis B-related liver cancer patients receiving immunotherapy The comparative data with traditional targeted therapy brings new hope to the treatment of hepatitis B-related liver cancer patients worldwide.” said Fan Jia, academician of the Chinese Academy of Sciences and dean of Zhongshan Hospital affiliated to Fudan University.
On the 16th, Beijing time, Daboshu (sintilimab injection) led by Fan Jia combined with Dayoutong (bevacizumab injection) for the first-line treatment of advanced liver cancer. Randomized, controlled, open multicenter II /Phase III key clinical study (ORIENT-32) results were published in the top international biomedical journal "The Lancet·Oncology".
This clinical study uses the combined use of two national new drug special creation results.
The results of the study showed that the treatment plan prolonged the patient's progression-free survival and overall survival.
Specifically, the Sintilizumab combined with bevacizumab treatment regimen compared with traditional standard targeted drug therapy, the median overall survival (OS) was not reached and 10.4 months, respectively, and the risk of death was significantly reduced by 43%; medium Progression-free survival (PFS) was 4.6 months and 2.8 months, respectively, and the risk of disease progression was significantly reduced by 44%.
The median treatment duration of Sintilizumab is 7.0 months, Bevacizumab (Dalton) is 6.6 months, and targeted therapy is 3.5 months, indicating that patients in the immune combination group have better compliance , More able to tolerate continuous treatment.
"This research was published in the journal "The Lancet Oncology", which reflects the international oncology community's recognition of this high-quality Chinese original research." Fan Jia said that this is also the case for the entire research team and subjects in the new coronary pneumonia In the epidemic, the results achieved by overcoming the difficulties and joint efforts have provided another effective treatment for liver cancer patients in China and the world, which is of great significance for improving the efficacy and prognosis of liver cancer.
Medical experts point out that liver cancer is a common malignant tumor of the digestive system worldwide, and China's liver cancer patients account for about half of the global number.
China accounts for 55% of new liver cancers globally, of which 85% to 90% are hepatocellular carcinoma (HCC), which is mainly caused by hepatitis B virus and/or hepatitis C virus infection.
Prior to this, the National Medical Products Administration has accepted the application for new indications for the treatment of first-line liver cancer patients with Daboshu (sintilimab injection) in combination with Dayoutong (bevacizumab injection).
These two drugs are the major scientific and technological achievements of "Major New Drug Creation" and have been included in the national medical insurance catalogue.
Chen Kaixian, deputy chief technical engineer of the National New Drug Creation Project and academician of the Chinese Academy of Sciences, said that Daboshu and Dayou were developed by Cinda Biopharmaceuticals. Has achieved high international standards.
(Finish)